The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies

Emamat, Hadi; Tangestani, Hadith; Nasab, Mojgan Behrad; Ghalandari, Hamid; Hekmatdoost, Azita

doi:10.17179/excli2021-3815

Cited by 6 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Attempts have been made to establish an association between epicardial fat thickness and NAFLD. Systematic reviews consolidating various studies confirm the link between epicardial fat thickness and the presence and severity of NAFLD [ 13 , 14 ], including distinctions between different stages of liver fibrosis [ 15 - 17 ]. Exploring this relationship further in the context of organ donation is warranted.…”

Section: Discussionmentioning

confidence: 99%

CT-Based Hounsfield Units for Pre-donation Liver Steatosis Assessment: Enhancing Transplant Outcomes and Efficiency

Campsen,

Poole

2024

Cureus

View full text Add to dashboard Cite

Steatotic liver grafts are associated with increased post-transplant complications and graft failure. The field of transplantation faces a challenge in the absence of a reliable pre-donation protocol for quantitatively assessing steatosis in cadaveric liver grafts. Current pre-donation evaluation protocols often involve non-contrast computed tomography (CT) scans of the chest and/or abdomen as an initial step in organ donation assessment. These routine scans have the potential to identify and quantify hepatic fat content when more than 20% of the liver parenchyma is affected. By incorporating both abdominal and thoracic CT scans during the donor workup, an assessment of the quality of the liver and spleen can be achieved. Our study is based on the hypothesis that a precise pre-donation evaluation utilizing Hounsfield units (HU) derived from CT images of the liver and spleen can provide transplant programs with crucial data regarding the extent of steatosis. This approach is envisioned as a significant advancement that could potentially eliminate the need for preoperative liver biopsies by offering essential information to streamline the evaluation process.

show abstract

Section: Discussionmentioning

confidence: 99%

CT-Based Hounsfield Units for Pre-donation Liver Steatosis Assessment: Enhancing Transplant Outcomes and Efficiency

Campsen,

Poole

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…Conversely, reduced eGFR was not significantly associated with incident heart failure at normal albuminuria levels [ 36 ]. Although MAFLD has potential mechanisms involved in HF risks, including low-grade inflammation [ 37 ], the direct effect of inflammation on the myocardium [ 38 ], and increased epicardial fat tissue [ 39 , 40 ], proteinuria per se is a marker for generalized vascular endothelial dysfunction, which is likely to have a much stronger effect than that of fatty liver disease on HF [ 41 ] . Otherwise, insulin resistance might be a shared mechanism related to HF in patients with underlying DKD or MAFLD.…”

Section: Discussionmentioning

confidence: 99%

The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study

Lee

Yoo²,

Kim³

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Diabetes mellitus is a major risk factor for heart failure. A recent consensus statement recommended annual cardiac biomarker testing (e.g. natriuretic peptide or high-sensitivity cardiac troponin) for all patients with diabetes. We aimed to identify patients at a higher risk of hospitalization for heart failure among patients with type 2 diabetes to prioritize those who would require screening. Methods Overall, 1,189,113 patients who underwent two medical health checkup cycles (2009–2012 and 2011–2014) and had stable diabetic kidney disease (DKD) phenotype in the Korean National Health Insurance Service database were included in this study. After excluding those with concurrent proteinuria (PU) and reduced estimated glomerular filtration rate, three groups (no-DKD, PU+DKD, and PU−DKD) were identified. A fatty liver index of ≥ 60 was defined as metabolic dysfunction–associated fatty liver disease (MAFLD). Patients were followed up until December 2018 or until outcomes developed. The Cox proportional hazard model was used to compare the risk of hospitalization for heart failure across groups. Results During an average of 6.6 years of follow-up, 5781 patients developed hospitalization for heart failure. After adjusting for covariates, the risk of hospitalization for heart failure was highest in the PU+DKD group [HR 3.12, 95% CI (2.75–3.55)], followed by the PU−DKD group [HR 1.85, 95% CI (1.73–1.99)] using the no-DKD group as the reference category. The risk of hospitalization for heart failure was comparable regardless of MAFLD status in patients who already had DKD. However, in the no-DKD group, the risk of hospitalization for heart failure was 1.4 times higher in patients with MAFLD than in those without [HR 1.41, 95% CI (1.31–1.52)]. Conclusions In lines with the international consensus statement, we suggest that annual cardiac biomarker testing should be conducted at least in patients with DKD and/or MAFLD.

show abstract

“…On the other hand, accumulating compelling evidence indicates that the pathological consequence of NAFLD may promote the development of HFpEF. It is well known that NAFLD readily boosts systemic inflammation and has thicker epicardial adipose tissue (EAT) (17)(18)(19). In addition, a large number of other secretory factors are also released in NAFLD (20).…”

Section: Introductionmentioning

confidence: 99%

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Yang

Tian²,

Zhang³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.

show abstract

The association between epicardial adipose tissue and non-alcoholic fatty liver disease: A systematic review of existing human studies

Cited by 6 publications

References 42 publications

CT-Based Hounsfield Units for Pre-donation Liver Steatosis Assessment: Enhancing Transplant Outcomes and Efficiency

CT-Based Hounsfield Units for Pre-donation Liver Steatosis Assessment: Enhancing Transplant Outcomes and Efficiency

The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of heart failure in type 2 diabetes: a retrospective cohort study

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Contact Info

Product

Resources

About